Abstract 2295P
Background
MET rearrangements are found in multiple cancers. Despite the availability of effective MET drugs there is no approved treatment for these tumors. We determined the prevalence of MET fusions, explored MET therapy in preclinical models and assessed efficacy of MET tyrosine kinase inhibitors (TKI) in a colorectal cancer (CRC) patient with MET fusion.
Methods
We analyzed the AACR project GENIE registry (release V13, 167,423 samples from 148,268 patients) for intergenic MET fusions. We also identified 2 CRC patients (Lenox Hill Hospital, New York, NY, and Renji Hospital Shanghai, China, respectively) by RNA-based NGS. MET expression was assessed by IHC. Sensitivity of SJ-GBM2 (CLIP::MET, glioblastoma), and H1993 and EBC1 (MET amplified lung cancer) cells to type 1 and type 2 MET TKIs were assessed.
Results
We identified 44/148,286 patients (0.03%) with an intergenic MET fusion; cancer types included brain (n=12; with 8 high-grade gliomas), NSCLC (n = 11 with 9 adenocarcinomas), gastrointestinal tract (n = 8; with 3 esophageal adenocarcinomas, 3 cholangiocarcinomas), etc. Recurrent fusion partners accounted for 18/44 (40.1%) cases and included 7 PTPRZ1, 5 ST7, 3 CTTNBP2, 2 CAPZA2 and 2 DOCK4. Two CRC patients with MET fusions (SYNRG2::MET, ZKSCAN1::MET) were found from routine NGS screening and both showed strong MET expression. Treatment with type 2 (cabozantinib) or type 1 (crizotinib, capmatinib, savolitinib) MET TKIs blocked growth of SJ-GBM2 cells with IC50 values of 0.3, 0.2, 0.1 and 0.04 μM, respectively, reflecting the sensitivity observed in H1993 and EBC1. MET TKIs blocked MET, AKT, ERK and S6 phosphorylation in SJ-GBM2 cells. These results were recapitulated with MET shRNAs. The CRC patient (SYNRG2::MET fusion) failed several lines of chemotherapy and was then treated with crizotinib, achieving a mixed response, with stable disease in lung metastases. Upon progression the patient was treated with capmatinib and a decrease in CEA from was observed after 3 weeks on therapy.
Conclusions
Our findings indicate MET fusions are widely distributed among tumor types and are sensitive to type 1 and type 2 MET TKIs. Clinical trials evaluating MET inhibitors for patients whose cancers are driven by MET fusions are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NIH.
Disclosure
M. Ladanyi: Financial Interests, Advisory Board: Merck, Bristol Myers Squibb, Takeda, Bayer, Lilly Oncology, Janssen, Paige.AI; Non-Financial Interests, Research Grant: Merus, Loxo Oncology, Elevation Oncology Inc., Hellsin. R. Somwar: Non-Financial Interests, Research Grant: Merus, Loxo Oncology, Elevation Oncology Inc., Hellsin. All other authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08